S‑1‑containing chemotherapy for patients with non‑small‑cell lung cancer: A population‑based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

  • Authors:
    • Masaharu Inagaki
    • Yoko Shinohara
    • Takayuki Kaburagi
    • Takeo Endo
    • Shinsuke Homma
    • Nobuyuki Hizawa
    • Koji Kishi
    • Hiroyuki Nakamura
    • Kenji Hayashihara
    • Takefumi Saito
    • Koichi Kurishima
    • Hiroichi Ishikawa
    • Hideo Ichimura
    • Takeshi Nawa
    • Norihiro Kikuchi
    • Kunihiko Miyazaki
    • Takahide Kodama
    • Hiroaki Satoh
    • Kinya Furukawa
  • View Affiliations

  • Published online on: March 21, 2016     https://doi.org/10.3892/mco.2016.826
  • Pages: 1025-1030
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To evaluate the efficacy and safety of S‑1 monotherapy, S‑1‑containing combined chemotherapy and S‑1 containing chemoradiotherapy for non‑small cell lung cancer (NSCLC), a population‑based observational study was performed. The efficacy and safety of the chemotherapies were evaluated at 13 institutes in a prefecture of Japan between April 2011 and March 2015. Datasets were obtained from 282 patients with NSCLC. For either wild‑type or mutated epidermal growth factor receptor (EGFR), these three therapy groups generated almost identical response results and toxicity profiles as those in previously reported clinical trials, although the present study appeared to have slightly lower survival rates compared with those in the previous clinical trials. This may be due to the inclusion of patients in poor condition, and S‑1 therapy being administered in the second, or later, line of therapy. In conclusion, the present study has confirmed that S‑1‑containing chemotherapy is effective against wild‑ and mutated‑type EGFR NSCLC, and it is also tolerable in clinical practice.
View References

Related Articles

Journal Cover

June 2016
Volume 4 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Inagaki, M., Shinohara, Y., Kaburagi, T., Endo, T., Homma, S., Hizawa, N. ... Furukawa, K. (2016). S‑1‑containing chemotherapy for patients with non‑small‑cell lung cancer: A population‑based observational study by the Ibaraki thoracic integrative (POSITIVE) research group. Molecular and Clinical Oncology, 4, 1025-1030. https://doi.org/10.3892/mco.2016.826
MLA
Inagaki, M., Shinohara, Y., Kaburagi, T., Endo, T., Homma, S., Hizawa, N., Kishi, K., Nakamura, H., Hayashihara, K., Saito, T., Kurishima, K., Ishikawa, H., Ichimura, H., Nawa, T., Kikuchi, N., Miyazaki, K., Kodama, T., Satoh, H., Furukawa, K."S‑1‑containing chemotherapy for patients with non‑small‑cell lung cancer: A population‑based observational study by the Ibaraki thoracic integrative (POSITIVE) research group". Molecular and Clinical Oncology 4.6 (2016): 1025-1030.
Chicago
Inagaki, M., Shinohara, Y., Kaburagi, T., Endo, T., Homma, S., Hizawa, N., Kishi, K., Nakamura, H., Hayashihara, K., Saito, T., Kurishima, K., Ishikawa, H., Ichimura, H., Nawa, T., Kikuchi, N., Miyazaki, K., Kodama, T., Satoh, H., Furukawa, K."S‑1‑containing chemotherapy for patients with non‑small‑cell lung cancer: A population‑based observational study by the Ibaraki thoracic integrative (POSITIVE) research group". Molecular and Clinical Oncology 4, no. 6 (2016): 1025-1030. https://doi.org/10.3892/mco.2016.826